Shares of the South San Francisco-based firm's stock (NASDAQ:CEGE) hit rock bottom on the news, tumbling 72 percent, or 44 cents, to close Thursday at a meager 17 cents. It's a record low for the company, which had traded close to the $3 mark in late August before falling 70 percent when its other Phase III study of GVAX was terminated due to an imbalance of deaths in the treatment arm. (BioWorld Today) Read More
